A. Menarini Industrie Farmaceutiche Riunite Srl:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:A. Menarini Industrie Farmaceutiche Riunite Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3327
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company’s products portfolio is focused on a several therapeutic and wellness areas including allergy, andrology, antinfective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women’s wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, and others. Menarini operates through its manufacturing sites, research and development centers and has presence across Europe and Asia, Africa, Central and South America. It distributes products across several countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.

A. Menarini Industrie Farmaceutiche Riunite Srl – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For US$80 Million 14
Partnerships 15
Melinta Therapeutics Enters into Agreement with Menarini 15
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16
Menarini Asia-Pacific Enters into Agreement with Merck 17
Menarini Forms Joint Venture with BiosYnth 18
Moberg Extends Distribution Agreement with Menarini for Emtrix 19
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20
Moberg Pharma Extends Distribution Agreement With Menarini 21
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25
Licensing Agreements 26
Menarini Enters into Licensing Agreement with Daiichi Sankyo 26
Berlin-Chemie Enters into Licensing Agreement with Selvita 27
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 28
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 29
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 30
Vivus Enters Into Licensing Agreement With Menarini For Spedra 31
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 33
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 34
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 35
FAES Farma Enters into License Agreement with Menarini For Bilastina 36
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 37
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 39
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 40
Acquisition 41
Menarini Group Plans To Acquire Indian Pharma Company 41
A. Menarini Industrie Farmaceutiche Riunite Srl – Key Competitors 42
A. Menarini Industrie Farmaceutiche Riunite Srl – Key Employees 43
A. Menarini Industrie Farmaceutiche Riunite Srl – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 47
Recent Developments 48
Strategy And Business Planning 48
Mar 13, 2017: Menarini Arrives In Columbia And Peru Two New Offices For A Stronger Connection Between Two Continents 48
Jan 18, 2017: Menarini In Turkey: +25% Growth In 2016 And New Headquarters In Istanbul 49
Corporate Communications 50
Jun 29, 2017: Menarini Increases Number of Members of the Board – for the First Time External Members In Majority 50
Product News 51
Apr 12, 2017: Menarini Brings Sirmione Thermal Water Into Italian Homes 51
03/17/2017: Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Key Facts, 2017 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For US$80 Million 14
Melinta Therapeutics Enters into Agreement with Menarini 15
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16
Menarini Asia-Pacific Enters into Agreement with Merck 17
Menarini Forms Joint Venture with BiosYnth 18
Moberg Extends Distribution Agreement with Menarini for Emtrix 19
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20
Moberg Pharma Extends Distribution Agreement With Menarini 21
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25
Menarini Enters into Licensing Agreement with Daiichi Sankyo 26
Berlin-Chemie Enters into Licensing Agreement with Selvita 27
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 28
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 29
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 30
Vivus Enters Into Licensing Agreement With Menarini For Spedra 31
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 33
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 34
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 35
FAES Farma Enters into License Agreement with Menarini For Bilastina 36
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 37
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 39
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 40
Menarini Group Plans To Acquire Indian Pharma Company 41
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Competitors 42
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Employees 43
A. Menarini Industrie Farmaceutiche Riunite Srl, Subsidiaries 44
A. Menarini Industrie Farmaceutiche Riunite Srl, Joint Venture 47

List of Figures
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[A. Menarini Industrie Farmaceutiche Riunite Srl:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bilcare Ltd (526853):企業の財務・戦略的SWOT分析
    Bilcare Ltd (526853) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Odebrecht S.A.:戦略・SWOT・企業財務分析
    Odebrecht S.A. - Strategy, SWOT and Corporate Finance Report Summary Odebrecht S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Delta NV-エネルギー分野:企業M&A・提携分析
    Summary Delta N.V. (Delta) is an independent multi-utility company. It provides energy, network and infrastructure services, and digital services. The company generates electricity, transmits and trades in energy, and supplies gas and power. Delta provides cable services for both analogue and digita …
  • The Cooper Companies Inc (COO):企業の財務・戦略的SWOT分析
    The Cooper Companies Inc (COO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ok Tedi Mining Ltd:企業の戦略・SWOT・財務情報
    Ok Tedi Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Ok Tedi Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Crescita Therapeutics Inc (CTX):企業の財務・戦略的SWOT分析
    Summary Crescita Therapeutics Inc (Crescita Therapeutics) is a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premi …
  • China Construction Bank Corp:企業のM&A・事業提携・投資動向
    China Construction Bank Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Construction Bank Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Johnson Electric Holdings Limited:企業の戦略・SWOT・財務分析
    Johnson Electric Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Johnson Electric Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Pier 1 Imports, Inc.:企業の戦略・SWOT・財務情報
    Pier 1 Imports, Inc. - Strategy, SWOT and Corporate Finance Report Summary Pier 1 Imports, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • YGM Trading Ltd.:企業の戦略・SWOT・財務情報
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Hess Corp (HES):石油・ガス:M&Aディール及び事業提携情報
    Summary Hess Corp (Hess) is a global independent energy company which carries out the exploration and production of crude oil and natural gas. It primarily operates in US, Denmark, the Joint Development Area of Malaysia/Thailand (JDA), and Malaysia. It offers fee-based services including gathering, …
  • Extendicare Inc.
    Extendicare Inc. - Strategy, SWOT and Corporate Finance Report Summary Extendicare Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sublimity Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Sublimity Therapeutics Ltd(Sublimity) formerly known as Sigmoid Pharma Ltd, focuses on the development of therapeutics for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The company’s product portfolio includes cyclosporine, oral vaccines, oral peptides an …
  • University of British Columbia-製薬・医療分野:企業M&A・提携分析
    Summary University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its stude …
  • South Egypt Drug Industries Co:企業の戦略的SWOT分析
    South Egypt Drug Industries Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Adhera Therapeutics (MRNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and …
  • Suncorp Group Ltd:戦略・SWOT・企業財務分析
    Suncorp Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Suncorp Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • MemorialCare Health System-製薬・医療分野:企業M&A・提携分析
    Summary MemorialCare Health System (MemorialCare) is a nonprofit health system that offers medical services. The center offers care services such as stroke care, cancer care, rehabilitation and physical therapy, weight-loss surgery, heart and vascular care, breast care, imaging and radiology, labora …
  • Flight Centre Travel Group Limited (FLT):企業の財務・戦略的SWOT分析
    Flight Centre Travel Group Limited (FLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • United Utilities Group Plc (UU):企業の財務・戦略的SWOT分析
    United Utilities Group Plc (UU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆